vascular disease News
-
£1.1 million project to develop new biodegradable stents
A £1.1 million project to develop biodegradable stents for patients with severe vascular disease, which affects around one million people in the UK, has started thanks to Innovate UK funding. The unique project, a collaboration between the UK-based medical device company Arterius and the Translational Biomedical Research Centre (TBRC) at the University of Bristol, will develop a new type of ...
-
Symic Bio Announces 12-Month Results from the SHIELD Trial of SB-030 in Peripheral Vascular Disease
SAN FRANCISCO, April 2, 2018 – Symic Bio, a biopharmaceutical company developing novel matrix-targeting biotherapeutics, today announced 12-month results from the Phase 1/2 SHIELD trial evaluating SB-030 in patients with peripheral vascular disease undergoing angioplasty. Under an extended trial protocol allowing assessment of secondary endpoint measurements at 12 months following ...
-
Soundbite Medical Enters Into A License Agreement With VFLO Medical To Bring Its Products To Greater China
Soundbite Medical Solutions Inc. (SBMS), a medical device company dedicated to developing solutions for the interventional treatment of calcific occlusive peripheral and coronary arterial diseases, today announced that it has entered into an exclusive license agreement with VFLO Medical (VFLO). Pursuant to the agreement, Soundbite has granted to VFLO an exclusive license for certain proprietary ...
-
Results from Symic Bio Liver Fibrosis Program Presented at the International Liver Congress 2018
SAN FRANCISCO, April 16, 2018 – Symic Bio, a biopharmaceutical company developing novel biotherapeutics targeting the extracellular matrix, presented results from a lead candidate therapy for liver fibrosis at the International Liver Congress 2018, the annual meeting of the European Association for the Study of the Liver, held April 11-15, 2018, in Paris. Results demonstrated that treatment ...
-
Imperative Care Raises $260 Million to Advance Innovations that Elevate Stroke Care
Imperative Care, Inc. today announced that it has closed a $260 million Series D financing led by D1 Capital Partners L.P. New investors HealthCor Investments LLC and Innovatus Capital Partners, LLC also joined the round. Existing Imperative Care investors Ally Bridge Group, Bain Capital Life Sciences, Ascension Ventures, Delos Capital, Rock Springs Capital, and Amed Ventures participated in the ...
-
Robocath successfully performs first carotid stenting in France with R-One robot at Rennes University Hospital
Robocath, a company that designs, develops and commercializes innovative robotic platforms for the treatment of vascular diseases, announces today its successful first robotic carotid stenting at Rennes University Hospital. This breakthrough in the neurovascular field was performed on November 16, using Robocath’s R-One robot, operated by Dr. François Eugène and his team. The ...
By Robocath
-
2,000,000 TWO2 Treatments Milestone Reached as TWO2 Study Is Highlighted in Systemic Review of Topical Oxygen Therapies
Advanced Oxygen Therapy Inc. (AOTI) today announced that 2,000,000 treatments of its unique cyclical-pressure Topical Wound Oxygen (TWO2) therapy have now been applied by patients safely at home. Additionally, a high-quality paper published on April 19, 2021 in the journal Diabetic Medicine, entitled Topical oxygen therapy for diabetes-related foot ulcers: A systematic review and ...
-
Imperative Care Appoints Three to Its Board of Directors
Holly Sheffield, Medical Technology Executive and Investment Banker Hank Plain, Serial Entrepreneur, Executive and Venture Capital Leader James Rogers, Public and Private Medical Technology Investor Imperative Care, Inc. today announced three appointments to the company’s Board of Directors with the addition of Holly Sheffield, Hank Plain, and James Rogers. “We are grateful to ...
-
SoundBite Medical Solutions Announces First Use of its Novel 0.014” Active Wire to Successfully Treat Calcified Below-The-Knee CTOs
Soundbite Medical Solutions Inc. (SBMS) announced today the first use of its novel Active Wire 0.014” platform in the successful treatment of patients suffering from critical limb ischemia (CLI) with heavily calcified below-the-knee (BTK) chronic total occlusions (CTO). The procedures were performed by Professor Marianne Brodmann, Head of the Clinical Division of Angiology, Department of ...
-
Om pharma wins the 2021 Geneva Economy Award
The award will be presented this evening by the Geneva Chamber of Commerce, Industry and Services (CCIG), the State of Geneva, the Office for the Promotion of Industries and Technologies (OPI) and the Office for the Promotion of Equality and Prevention of Violence (BPEV), during a ceremony at the ‘Bâtiment des Forces Motrices’ in Geneva. The Geneva Economy and Innovation ...
-
Centerline Biomedical Awarded $1.5M Phase II NIH SBIR Grant to Advance Development of Next-Generation IOPS Technology
Centerline Biomedical, Inc. (Centerline) announced on April 21, 2020 the receipt of a Direct to Phase II Small Business Innovation Research (SBIR) grant award from the National Heart, Lung, and Blood Institute of the National Institutes of Health (NIH). This represents the fourth small business grant awarded to the startup founded to commercialize and innovate IOPS™, a novel image guidance ...
-
Alucent Biomedical Announces $35 Million Series B Financing Led By A Multinational Strategic Investor
Alucent Biomedical, a privately held medical technology company founded to transform the way vascular disease is treated, today announced the close of a $35 million Series B financing round led by a large multinational strategic investor and joined by another new investor, Fresenius Medical Care Ventures. Alucent was founded by the Avera Research Institute, an arm of Avera Health, which also ...
-
Expansion of Topical Wound Oxygen (TWO2) Product Family Extends Treatment to Chronic Wound Patients with Larger Limbs, Venous and Diabetic Foot Ulcers
AOTI Inc. announced today an eagerly anticipated expansion of its unique multi-modality Topical Wound Oxygen (TWO2) therapy product family. The addition of a new larger extremity-chamber to the company’s peripheral vascular disease (PVD) focused product line, allows for the application of TWO2 treatments for many more patients suffering from costly nonhealing chronic wounds. Especially ...
-
UNITY Biotechnology Presentations at ARVO 2022 Showcase UBX1325 as an Investigational Novel Therapeutic Modality for Retinal Vascular Diseases
UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, announced presentations at the Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Meeting featuring UBX1325 as a potential treatment for diabetic macular edema (DME) and wet age-related macular degeneration (AMD), as well ...
-
Stanford Surgeon Venita Chandra Joins Alucent Biomedical Scientific Advisory Board as Company Enters Arteriovenous Fistula Market
Alucent Biomedical, a privately held medical technology company founded to transform the way vascular disease is treated, today announced Venita Chandra, M.D., will join the company’s scientific advisory board. Dr. Chandra is board certified in both general and vascular surgery. She is a clinical associate professor of surgery in the Division of Vascular Surgery at Stanford University ...
-
Studies suggest Elucid’s AI software helps to objectively quantify key drivers of stroke and heart attack from computed tomography angiography (CTA)
Computed tomography angiography (CTA) has been increasingly used in the diagnosis of vascular disease and its a modality that offers many potential clinical benefits. The question is, how to actualize that benefit and get the most our of the modality. Elucid has developed an artificial intelligence software that might just answer that question. How AI Can Improve CTA Analysis ...
By Elucid
-
Arterius Appoints Stever Parker as new Chief Executive Officer
Arterius Limited, a Leeds-based, UK company developing innovative medical devices with a focus on next generation bioresorbable coronary and peripheral stents, has announced that it has appointed Steve Parker as Chief Executive Officer. In the role Steve will lead the next phase of developing and scaling the business as it moves closer to commercialization of it’s suite of innovative and ...
-
Robocath concludes first European clinical study to demonstrate safety and efficacy of robotic coronary angioplasty performed with R-One
Robocath, a company that designs, develops and commercializes innovative robotic platforms for the treatment of vascular diseases, announces today that it has concluded its ‘R-Evolution’ clinical study. The study was aimed at assessing the safety and efficacy of the R-OneTM robotic assistance platform. Sixty-two patients across six European hospital centers participated: the ...
By Robocath
-
Robocath successfully completes first robotic coronary angioplasties in Belgium
Robocath, a company that designs, develops and commercializes cardiovascular robotic platforms for the treatment of vascular diseases, today announces the successful completion of first five robotic coronary angioplasties in Belgium. The Percutaneous Coronary Interventions (PCI) were performed on April 8 and 13 by Prof. Stefan Verheye, a recognized and highly experienced interventional ...
By Robocath
-
Tissue Genesis, LLC Provides Cell Isolation Processing for Patients with Critical Limb Ischemia (CLI) in Ukrainian Clinical Study
Tissue Genesis, LLC, the leading provider of cell isolation technology is pleased to announce that the Icellator® is being used to generate therapeutic cell preparations at the V.P. Komisarenko Institute of Endocrinology and Metabolism in Kiev, Ukraine, for patients with critical limb ischemia (CLI). The autologous stem-cell therapy, which utilizes a patient’s own fat cells, is the ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you